Literature DB >> 12598438

Blindness: how to assess numbers and causes?

O E Babalola1, I E Murdoch, S Cousens, A Abiose, B Jones.   

Abstract

BACKGROUND: Traditionally, blindness surveys have modelled themselves on the "gold standard" of a census and examination of a whole population. Blindness, however, is a relatively rare condition even in badly affected communities; hence, large sample sizes are required to gain adequate estimates of prevalence, particularly by cause.
METHODS: Three assessments of blindness prevalence and aetiology in the same communities are reported. One involved asking individuals questions concerning their visual status during a census (perceived visual status, PVD), one involved examination of all ostensibly visually disabled people presenting to a central point within each community (examination of the visually disabled, EVD), and the final assessment involved a gold standard examination of the whole population (whole community examination, WCE).
RESULTS: In a population of 8139 the blindness prevalence was 2.7% PVS, 3.6% EVD, and 3.1% WCE. Attributed causes of blindness were not representative in the PVS except for cataract. The END yielded cause specific estimates not far from those found at WE except for a relative under-representation of glaucoma and optic atrophy.
CONCLUSION: Since cataract is, by a significant margin, the most common cause of blindness in the world such a simple method as asking individuals if they are blind and what they believe to be the cause may yield adequate estimates of the problem for planning eye care strategies for this condition. Alternatively, an ophthalmologist visiting villages and examining allcomers for visual disability may provide reasonably accurate cause specific prevalence estimates without the expense of a major blindness survey.

Entities:  

Mesh:

Year:  2003        PMID: 12598438      PMCID: PMC1771535          DOI: 10.1136/bjo.87.3.282

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

1.  Cataract and "Vision 2020-the right to sight" initiative.

Authors:  A Foster
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

2.  National survey of blindness and low vision in The Gambia: results.

Authors:  H Faal; D Minassian; S Sowa; A Foster
Journal:  Br J Ophthalmol       Date:  1989-02       Impact factor: 4.638

3.  A simplified methodology for the assessment of blindness and its main causes.

Authors:  B Thylefors
Journal:  World Health Stat Q       Date:  1987

4.  Red-dot card test of the paracentral field as a screening test for optic nerve disease in onchocerciasis.

Authors:  I Murdoch; B R Jones; O E Babalola; S N Cousens; I Bolarin; A Abiose
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

5.  A comprehensive assessment of visual impairment in a population of older Americans. The SEE Study. Salisbury Eye Evaluation Project.

Authors:  G S Rubin; S K West; B Muñoz; K Bandeen-Roche; S Zeger; O Schein; L P Fried
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-03       Impact factor: 4.799

6.  Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis.

Authors:  A Abiose; B R Jones; S N Cousens; I Murdoch; A Cassels-Brown; O E Babalola; N D Alexander; I Nuhu; J Evans; U F Ibrahim
Journal:  Lancet       Date:  1993-01-16       Impact factor: 79.321

7.  Distribution and aetiology of blindness and visual impairment in mesoendemic onchocercal communities, Kaduna State, Nigeria. Kaduna Collaboration for Research on Onchocerciasis.

Authors:  A Abiose; I Murdoch; O Babalola; S Cousens; I Liman; J Onyema; J Evans; W Gregory; B Jones
Journal:  Br J Ophthalmol       Date:  1994-01       Impact factor: 4.638

  7 in total
  1 in total

1.  The Nigerian national blindness and visual impairment survey: Rationale, objectives and detailed methodology.

Authors:  Brendan Dineen; Clare E Gilbert; Mansur Rabiu; Fatima Kyari; Abdull M Mahdi; Tafida Abubakar; Christian C Ezelum; Entekume Gabriel; Elizabeth Elhassan; Adenike Abiose; Hannah Faal; Jonathan Y Jiya; Chinenyem P Ozemela; Pak Sang Lee; Murthy V S Gudlavalleti
Journal:  BMC Ophthalmol       Date:  2008-09-22       Impact factor: 2.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.